Related Experiment Video
Updated: Jun 2, 2026
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Quebec platelet disorder
Catherine P M Hayward1, Georges E Rivard
1Departments of Pathology and Molecular Medicine, Michael G DeGroote Centre for Learning, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada. haywrdc@mcmaster.ca
Insights
Quebec platelet disorder (QPD) is a bleeding disorder caused by a PLAU gene mutation. This defect leads to overactive platelets, impacting fibrinolysis and causing bleeding issues.
Area of Science:
- Hematology
- Genetics
- Molecular Biology
Background:
- Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder.
- It is characterized by a gain-of-function defect in fibrinolysis.
- Recent advances have elucidated its genetic cause and pathogenesis.
Purpose of the Study:
- To summarize expert opinions on QPD features.
- To review recent advances in understanding QPD pathogenesis.
- To highlight the genetic cause of QPD.
Main Methods:
- Review of recent scientific literature.
- Expert opinion synthesis.
- Analysis of genetic and molecular mechanisms.
Main Results:
- QPD is caused by a copy number variation mutation in the PLAU gene.
- This mutation leads to urokinase plasminogen activator (uPA) overexpression during megakaryopoiesis.
- Results in profibrinolytic platelets with active uPA in α-granules.
Conclusions:
- QPD is the first bleeding disorder linked to a PLAU mutation.
- It is also the first identified bleeding disorder resulting from a gene copy number mutation.
- Understanding the molecular defect provides insights into fibrinolysis regulation.
Abstract:
Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with a unique gain-of-function defect in fibrinolysis. In the past 5 years, there have been important advances in the understanding of the pathogenesis of QPD, including its genetic cause, which is a copy number variation mutation of PLAU, the gene for urokinase plasminogen activator (uPA). QPD is the first bleeding disorder identified to be caused by a PLAU mutation and it is also the first bleeding disorder recognized to result from a gene copy number mutation. The molecular defect of QPD leads to marked overexpression of uPA during megakaryopoiesis, producing profibrinolytic platelets that contain active forms of uPA in their α-granules. This article summarizes expert opinions on the features of QPD and recent advances in the understanding of its pathogenesis and genetic cause.
Related Concept Videos
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...